PASG vs. CRIS, ALVR, CVM, OTLK, GRTS, BLUE, PLX, ATHA, SGMO, and JATT
Should you be buying Passage Bio stock or one of its competitors? The main competitors of Passage Bio include Curis (CRIS), AlloVir (ALVR), CEL-SCI (CVM), Outlook Therapeutics (OTLK), Gritstone bio (GRTS), bluebird bio (BLUE), Protalix BioTherapeutics (PLX), Athira Pharma (ATHA), Sangamo Therapeutics (SGMO), and JATT Acquisition (JATT). These companies are all part of the "biological products, except diagnostic" industry.
Passage Bio (NASDAQ:PASG) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings, community ranking and profitability.
Passage Bio currently has a consensus price target of $9.33, indicating a potential upside of 522.22%. Curis has a consensus price target of $37.33, indicating a potential upside of 128.34%. Given Passage Bio's higher probable upside, equities research analysts plainly believe Passage Bio is more favorable than Curis.
In the previous week, Curis had 12 more articles in the media than Passage Bio. MarketBeat recorded 12 mentions for Curis and 0 mentions for Passage Bio. Passage Bio's average media sentiment score of 0.00 beat Curis' score of -0.24 indicating that Passage Bio is being referred to more favorably in the media.
Passage Bio has a net margin of 0.00% compared to Curis' net margin of -473.04%. Passage Bio's return on equity of -73.12% beat Curis' return on equity.
Passage Bio has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Comparatively, Curis has a beta of 3.59, meaning that its share price is 259% more volatile than the S&P 500.
Curis received 638 more outperform votes than Passage Bio when rated by MarketBeat users. Likewise, 67.55% of users gave Curis an outperform vote while only 66.20% of users gave Passage Bio an outperform vote.
Curis has higher revenue and earnings than Passage Bio. Curis is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.
53.5% of Passage Bio shares are held by institutional investors. Comparatively, 30.0% of Curis shares are held by institutional investors. 4.3% of Passage Bio shares are held by company insiders. Comparatively, 5.7% of Curis shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Curis beats Passage Bio on 8 of the 15 factors compared between the two stocks.
Get Passage Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for PASG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PASG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Passage Bio Competitors List
Related Companies and Tools
